What they were paid
Jazz Pharmaceuticals Director Compensation Table · all 2 fiscal years held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $127,500 | $393,064 | $0 | $0 | $520,564 |
| FY2024 | $111,692 | $422,573 | $0 | $0 | $534,265 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Jazz Pharmaceuticals plc DEF 14A filed June 8, 2026, accession 0001232524-26-000029, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Jazz Pharmaceuticals pays directors a $75,000 cash retainer and $400,000 in equity.
Committees
FY2025 · as the proxy prints themCompensation (Chair) · SMC
The rest of the Jazz Pharmaceuticals board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Anne O'Riordan | Independent Director | $495,564 |
| Bruce C. Cozadd | Chair of the Board | $0 |
| Heather Ann McSharry | Independent Director | $528,064 |
| Laura J. Hamill | Independent Director | $480,564 |
| Mark D. Smith | Independent Director | $490,564 |
| Norbert G. Riedel | Independent Director | $518,064 |
| Patrick G. Enright | Independent Director | $495,564 |
| Patrick Kennedy | Independent Director | $503,064 |
| Renee D. Gala | Director | $0 |
| Rick E Winningham | Lead Independent Director | $555,564 |
| Seamus C. Mulligan | Independent Director | $500,564 |
| Ted W. Love | Independent Director | $8,542 |
The full Jazz Pharmaceuticals compensation record
free company briefThis page is one director within Jazz Pharmaceuticals's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat